A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL). The authors explained that while molecularly targeted therapies like Bruton ...
Venetoclax-obinutuzumab therapy shows sustained PFS and OS benefits over chemoimmunotherapy in untreated CLL patients with coexisting conditions. The CLL14 trial's 6-year follow-up confirms >50% of ...
Senior Lecturer of Exercise Immunology, Faculty of Health and Medical Sciences, School of Biosciences, University of Surrey CLL starts when a type of immune cell called a B cell – normally responsible ...
Overwhelmed. That’s how some people describe chronic lymphocytic leukemia (CLL) diagnosis. Especially when you’re told to “watch and wait” rather than start treatment. Over 23,000 people in the U.S.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results